Study overview

Heart failure is a condition that has considerable impact on the health of Australians. The frequency of self-reported heart failure increased from 110,000 to 143,700 people between the 2017–18 and 2022 National Health Surveys (ABS 2023; ABS 2017-18).  In 2022, heart failure and cardiomyopathy contributed to 15% of deaths in Australia and 1.5% of all hospitalisations in 2021–22 (AIHW 2024). 

Effective health care in the community can help people with heart failure keep well and remain out of hospital for longer. Measures of mortality and readmissions among people hospitalised with heart failure are used as indicators of health system and hospital performance both in Australia and internationally (ACSQHC 2021; OCED 2023). 

Data available in the National Health Data Hub (NHDH) allows the health care pathways of people hospitalised with heart failure in Australia to be explored. Through administrative data, it captures health services and medications people accessed after hospital discharge, readmission to hospital, residential aged care stays and mortality. 

This project aims to describe the characteristics of people hospitalised with heart failure in Australia and illustrate their care in hospital and as they transition back into the community. 

The key research questions this project explored are:

  • What are the characteristics of people hospitalised with heart failure?
  • What kinds of community-based care do people access following a heart failure related hospitalisation? Does care vary among population subgroups? 
  • What are the health outcomes of people in the one year following a heart failure hospitalisation?

Box 1. What is heart failure?

Heart failure occurs when the heart functions less effectively in pumping blood around the body. It can occur suddenly, although it usually develops slowly as the heart gradually becomes weaker. Heart failure can result from a variety of diseases and conditions that impair or overload the heart. These include heart attack, high blood pressure, damaged heart valves or cardiomyopathy. 
Cardiomyopathy is where the entire heart muscle, or a large part of it, is weakened. Cardiomyopathy and heart failure commonly occur together. Selected cardiomyopathy codes have been included in the identification of the heart failure cohort as they are frequently associated with, or lead to, heart failure. 

Data

This study used the National Health Data Hub (NHDH) version (NIHSI 3.0). The NHDH links de-identified, person-level data from hospitals and emergency departments, aged care facilities, the Medicare Benefits Schedule, the Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme, the National Death Index and other data. The NHDH allows for person-centred analysis of health service use and health outcomes among those hospitalised with heart failure. 

The NHDH was formerly the National Integrated Health Services Information (NIHSI) analytical asset. The NIHSI version 3.0 used for this study included hospital data from 2010–11 to 2020–21 from New South Wales, Victoria, Queensland, South Australia, Tasmania and the Australian Capital Territory. For most states, the admitted patient care data were limited to only public hospitals. Results may not be generalisable to Western Australia and the Northern Territory. 

Further information

Cohort 

The cohort included 71,494 people who had a heart failure related hospitalisation in 2019. The cohort was limited to those who had an acute care type and were alive when discharged from hospital. In this report the first in-scope hospitalisation in 2019 for each person is referred to as their ‘index hospitalisation’. 

Further information

For additional information, see Technical notes: cohort selection 

Study periods

The study periods referred to in this report are illustrated in Figure 1. The cohort entry period of 2019 was chosen based on the availability of data for a one-year follow-up post index hospitalisation. For many in the cohort, the follow-up period will include a period in 2020 in which Australia’s population and health system was affected by the COVID-19 pandemic. For more information about how this may impact the results of the study, see Technical notes: limitations.

Figure 1: Study period

A timeline view of the study period including the start (1 July 2010), cohort entry start (1 January 2019) and end (31 December 2019), and end of 1 year follow up (31 December 2020).

A timeline view of the study period including the start (1 July 2010), cohort entry start (1 January 2019) and end (31 December 2019), and end of 1 year follow up (31 December 2020).

Key terms used in the report 

Below are selected key terms and concepts used in this report.